Laurantis Pharma

Laurantis Pharma is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. Its research aims to improve treatment options for patients with various diseases through cutting-edge technologies and solutions. Laurantis Pharma specializes in biopharmaceutical innovations aimed at improving treatment outcomes. Founded in Turku, Finland, the company has undergone strategic developments since its inception.

In April 2014, Hermo Pharma Oy Ltd acquired Laurantis Pharma, enhancing its financial resources and product portfolio. The company operates primarily from its headquarters in Turku, Finland, where it continues to pursue its mission in the healthcare sector. Laurantis Pharma delivers a range of biopharmaceutical products designed to tackle specific diseases. Its offerings encompass innovative therapies that target critical health issues, aiming to enhance patient outcomes.

The company primarily serves healthcare providers and institutions across North America, Europe, and selected regions in Asia, addressing the needs of both small clinics and large healthcare networks. In the most recent fiscal year of 2021, Laurantis Pharma reported no revenue, with an EBITDA of EUR -1,006,757. The company's revenue generation strategy includes plans for future product launches and market expansions to drive financial growth and sustainability. Laurantis Pharma is actively developing new biopharmaceutical products, with plans for several launches in the coming years.

The company aims to expand its market presence in North America and Asia by 2025, leveraging recent funding of EUR 5. 640 mn from investors such as Broadview Ventures and Helsinki University Funds. This funding will support product development and enable geographical expansion, following the acquisition by Hermo Pharma Oy, which was completed in April 2014.